BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15389126)

  • 1. Plasmin generation and D-dimer formation during cardiopulmonary bypass.
    Chandler WL; Velan T
    Blood Coagul Fibrinolysis; 2004 Oct; 15(7):583-91. PubMed ID: 15389126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kinetics of plasmin inhibition by aprotinin in vivo.
    Kang HM; Kalnoski MH; Frederick M; Chandler WL
    Thromb Res; 2005; 115(4):327-40. PubMed ID: 15668193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
    Eisses MJ; Velan T; Aldea GS; Chandler WL
    Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of fibrinolysis and platelet function to bleeding after cardiopulmonary bypass.
    Ray MJ; Marsh NA; Hawson GA
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):679-85. PubMed ID: 7865673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Centrifugal and roller pumps--are there differences in coagulation and fibrinolysis during and after cardiopulmonary bypass?
    Steinbrueckner BE; Steigerwald U; Keller F; Neukam K; Elert O; Babin-Ebell J
    Heart Vessels; 1995; 10(1):46-53. PubMed ID: 7730247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic elucidation of effects of tranexamic acid on fibrinolysis and bleeding during and after cardiopulmonary bypass surgery.
    Kojima T; Gando S; Morimoto Y; Mashio H; Goda Y; Kawahigashi H; Kemmotsu O
    Thromb Res; 2001 Dec; 104(5):301-7. PubMed ID: 11738071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
    Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
    Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass.
    Chandler WL
    J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):459-67. PubMed ID: 16085250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autotransfusion management during and after cardiopulmonary bypass alters fibrin degradation and transfusion requirements.
    Wiefferink A; Weerwind PW; van Heerde W; Teerenstra S; Noyez L; de Pauw BE; Brouwer RM
    J Extra Corpor Technol; 2007 Jun; 39(2):66-70. PubMed ID: 17672185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass.
    Chandler WL; Velan T
    Blood; 2003 Jun; 101(11):4355-62. PubMed ID: 12480702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer].
    Oikawa T; Muramatsu Y; Akashi S; Usui N
    Nihon Jinzo Gakkai Shi; 1997 Mar; 39(2):144-9. PubMed ID: 9134831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
    Ray MJ; Marsh NA
    Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basic Evaluation of the Newly Developed "Lias Auto P-FDP" Assay and the Influence of Plasmin-α2 Plasmin Inhibitor Complex Values on Discrepancy in the Comparison with "Lias Auto D-Dimer Neo" Assay.
    Kumano O; Ieko M; Komiyama Y; Naito S; Yoshida M; Takahashi N; Ohmura K; Hayasaki J; Hayakawa M
    Clin Lab; 2018 Apr; 64(4):433-442. PubMed ID: 29739066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets.
    Orchard MA; Goodchild CS; Prentice CR; Davies JA; Benoit SE; Creighton-Kemsford LJ; Gaffney PJ; Michelson AD
    Br J Haematol; 1993 Nov; 85(3):533-41. PubMed ID: 7510990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery.
    Gando S; Kameue T; Sawamura A; Hayakawa M; Hoshino H; Kubota N
    Thromb Res; 2007; 120(1):87-93. PubMed ID: 17023030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppressed fibrinolysis after administration of low-dose aprotinin: reduced level of plasmin-alpha2-plasmin inhibitor complexes and postoperative blood loss.
    Mastroroberto P; Chello M; Zofrea S; Marchese AR
    Eur J Cardiothorac Surg; 1995; 9(3):143-5. PubMed ID: 7540397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
    Chandler WL; Velan T
    Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of fibrin/fibrinogen degradation products reagents and their utility in critical care patients with enhanced fibrinolysis.
    Kumano O; Ieko M; Komiyama Y; Naito S; Yoshida M; Takahashi N; Ohmura K; Hayakawa M
    Int J Lab Hematol; 2021 Aug; 43(4):813-820. PubMed ID: 33301236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.